HAIKOU, China, Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its wholly-owned ...
(RTTNews) - China Pharma Holdings, Inc. (CPHI) said its subsidiary Hainan Helpson Medical & Biotechnology Co. has received the Drug Supplementary Application Approval Notice for its candesartan ...
Trondheim, Norway - Results of a randomized trial suggest that the angiotensin II receptor blocker candesartan (Atacand® - AstraZeneca) may provide effective prophylaxis against migraine headaches.
In this 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study, candesartan cilexetil was compared to losartan in 654 hypertensive patients from 72 sites throughout the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback